Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic Blood Sampling Clear all
Completed Phase 1 Interventional Results available

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 2:01 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Cigarette Harm Reduction With Electronic Cigarette Use

NCT03473483
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Toxicity, Nicotine Dependence, Cigarettes, Cardiovascular Risk Factor, Nicotine Withdrawal
Interventions
SREC
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

25-Hydroxyvitamin D Pharmacokinetic Study

NCT03401541
View directory record Official record
Conditions
Vitamin D Deficiency, Fat Malabsorption
Interventions
Calcifediol, Calciferol
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT00450827
View directory record Official record
Conditions
Neuroblastoma
Interventions
bevacizumab, filgrastim, autologous hematopoietic stem cell transplantation, iodine I 131 monoclonal antibody 3F8
Biological · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 2, 2026, 2:01 AM EDT
Recruiting Phase 1 Interventional

An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

NCT07729579
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Investigational drug, Photodynamic therapy
Drug · Device
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

NCT01593397
View directory record Official record
Conditions
Obesity
Interventions
Propofol and Fentanyl administration
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 2, 2026, 2:01 AM EDT
Completed No phase listed Observational

Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage

NCT02866877
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Pharmacokinetic modeling
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Not applicable Interventional

McLean and Genomind Prospective Study

NCT03113890
View directory record Official record
Conditions
Major Depressive Disorder, PTSD
Interventions
Phlebotomy - Folate, Cheek Swab, Self-report surveys
Genetic · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 4 Interventional Results available

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

NCT02392208
View directory record Official record
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 2, 2026, 2:01 AM EDT
Recruiting Phase 1 Interventional

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

NCT07084129
View directory record Official record
Conditions
Sepsis
Interventions
personalized dosing adjustment of vancomycin
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

NCT02197247
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing, Pharmacokinetic sampling - rifampicin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

NCT04331288
View directory record Official record
Conditions
Potential Treatment for Alcohol Dependence-Alcohol Interaction
Interventions
PT150, Beverage
Drug · Other
Lead sponsor
Pop Test Oncology LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

NCT02317016
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

NCT01027364
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
Factor IX (rFIXFc), rFIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Results available

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

NCT03864406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cobicistat, Darunavir/Cobicistat, Rivaroxaban
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genetic Variability in CYP2D6 in U.S Active Duty Population

NCT02960568
View directory record Official record
Conditions
Pharmacologic Action
Interventions
Primaquine
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 60 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 2, 2026, 2:01 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-881, HYQVIA, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 2, 2026, 2:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kaempferol Absorption and Pharmacokinetics Evaluation

NCT07322406
View directory record Official record
Conditions
No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions
Kaempferol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling

NCT05948085
View directory record Official record
Conditions
Healthy
Interventions
Zavegepant 10 mg IN
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

NCT00571961
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 2, 2026, 2:01 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 2, 2026, 2:01 AM EDT
Completed No phase listed Observational

Pharmacologic Impact on Sedation Assessments

NCT01105663
View directory record Official record
Conditions
Pediatric Acute Lung Injury
Interventions
Pharmacokinetic Sampling and pharmacogenetic analysis
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 2, 2026, 2:01 AM EDT